Table 2 Serious adverse events during treatment.
Romosozumab (n = 49) | Denosumab (n = 52) | |
|---|---|---|
Serious adverse events | ||
Mitral regurgitation | 1 (2.0) | 0 (0.0) |
Respiratory failure | 1 (2.0) | 0 (0.0) |
Pulmonary non-tuberculous mycobacterial infection | 0 (0.0) | 1 (1.9) |
